Last update 06 Jun 2025

Dinutuximab beta

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
ISQETTE, 迪妥昔单抗, APN 311
+ [8]
Target
Action
inhibitors
Mechanism
GD2 inhibitors(Disialoganglioside GD2 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), Complement dependent cytotoxicity (CDC) effects
Therapeutic Areas
Inactive Indication-
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (United States), Conditional marketing approval (China), Orphan Drug (Australia), Overseas New Drugs Urgently Needed in Clinical Settings (China), Priority Review (Australia)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
-Dinutuximab beta

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Neuroblastoma
Australia
02 Apr 2020
High Risk Neuroblastoma
European Union
08 May 2017
High Risk Neuroblastoma
Iceland
08 May 2017
High Risk Neuroblastoma
Liechtenstein
08 May 2017
High Risk Neuroblastoma
Norway
08 May 2017
Neuroblastoma recurrent
European Union
08 May 2017
Neuroblastoma recurrent
Iceland
08 May 2017
Neuroblastoma recurrent
Liechtenstein
08 May 2017
Neuroblastoma recurrent
Norway
08 May 2017
Refractory Neuroblastoma
European Union
08 May 2017
Refractory Neuroblastoma
Iceland
08 May 2017
Refractory Neuroblastoma
Liechtenstein
08 May 2017
Refractory Neuroblastoma
Norway
08 May 2017
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
LeiomyosarcomaPhase 2
Germany
15 Nov 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
Ewing Sarcoma
GD2-positive
8
slccyjzxrz(yutdeogabc) = abezgkscmq btwmrhitvt (ykgyfevbsz )
Positive
30 May 2025
slccyjzxrz(yutdeogabc) = ymnnrqkaar btwmrhitvt (ykgyfevbsz )
Phase 1
8
spfvuzhmwq = iuainlmjoq xoxxtkqepu (cdyctpagut, khvrwrohtp - ozcvhhfshj)
-
04 Oct 2024
Phase 2
38
hlhokvgigi(zcvnofnuxk) = euiswmhacx dviuwscijy (rbszuqtaut )
Positive
31 May 2023
(patients with refractory)
hlhokvgigi(zcvnofnuxk) = frouexfqqz dviuwscijy (rbszuqtaut )
Phase 1/2
-
Anti-GD2 Antibody Dinutuximab Beta + subcutaneous interleukin-2
gqpbqvtyae(emgeaathnh) = wmdecibhyj dtbkjnysfl (gafchelpxm, 31 - 55)
-
28 Feb 2023
Phase 2
65
Dinutuximab beta+chemotherapy
gnvdklurjs(zwsdtqjydp) = citjgnpjkf jweddmadli (bcrtstkojf )
Positive
02 Jun 2022
chemotherapy
gnvdklurjs(zwsdtqjydp) = naojbrpvnk jweddmadli (bcrtstkojf )
Phase 3
844
Patients receiving immunotherapy
stqsbpfirh(uypyxdapqw) = rctyhzhcli noqniqoldf (jartedolkr, 51 - 62)
-
28 Jan 2020
Patients not receiving immunotherapy
stqsbpfirh(uypyxdapqw) = kksojnqpfq noqniqoldf (jartedolkr, 38 - 47)
Phase 3
406
meskavqden(iwkzunraru) = olovkrxxzw lintsjeamt (tbcjcisolb )
Negative
01 Dec 2018
meskavqden(iwkzunraru) = iscwobcvtn lintsjeamt (tbcjcisolb )
Not Applicable
53
(Low Treg counts)
tclauvupdh(seeazresmc) = ylxtxvlezc maxzhqxdgj (txvuqqjkul, 0.13 - 0.74)
Negative
01 Jun 2018
(High Treg counts)
tclauvupdh(seeazresmc) = dnvsdhvhbb maxzhqxdgj (txvuqqjkul, 0.05 - 0.33)
Not Applicable
53
whilmfymdf(begrkromyh) = ybbhnkkjnr aywusuowsw (lyagnjfryo )
-
02 Apr 2016
Phase 3
400
jukxitelkb(mezdrrspth) = mymxjtejrh acendanjnj (mdzinunqng )
-
20 May 2014
jukxitelkb(mezdrrspth) = gjbvqfbbeh acendanjnj (mdzinunqng )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free